Sanofi opens cell culture plant at Industriepark Höchst
Pharmaceutical company strengthens integrated research and development platform
Sanofi commissioned its new cell culture plant at Industriepark Höchst in June 2011. The diversifyed healthcare company invested around EUR 30 million to build the plant, which will produce monoclonal antibodies using biotechnological processes. Monoclonal antibodies are highly specialized protein molecules that inhibit disease or marshal the body’s natural defenses against illness. These therapeutic antibodies can be used to help heal wounds and treat various forms of cancer, diabetes, autoimmune diseases and infections. Around 80 employees at the cell culture plant will produce the antibodies for preclinical and clinical trials. The cell culture plant – which more than doubles the cell culture production capacity at the site – has come online at the right time for Sanofi : it is focusing more and more on targeted biopharmaceutical therapies, a fast-growing worldwide market.
Reinforced market position
“I am thrilled that we have successfully expanded this cutting-edge technology within the group in Frankfurt,” explained Martin Siewert, General Manager of Sanofi -Aventis Deutschland GmbH. “The new cell culture plant adds a valuable component to our integrated research and development platform at the park and reinforces Sanofi ’s overall position in the biotech market.” Industriepark Höchst is the only Sanofi
site worldwide that has activities in every stage of drug discovery and development.
Categories
Investments
Countries
Companies
Latest news
Borealis Expands XLPE Production in Sweden to Meet Rising Demand for Cable Insulation Materials
The investment is part of Borealis and Borouge’s EUR 200 million “Building for the Future” commitment to provide customers with the advanced materials they need to deliver the power cables essentia...
Technip Energies awarded two services contracts for first-of-a-kind waste-to-methanol Ecoplanta project in Spain
Chemmed Cluster Tarragona →Technip Energies (PARIS:TE) has been awarded two engineering services contracts by Repsol for the development of the Ecoplanta Molecular Recycling Solutions (Ecoplanta) project, a first-of-a-kind w...
INEOS Styrolution marks milestone with first commercial delivery of recycled styrene monomer from Indaver
Port Of Antwerp →Recycled styrene monomer produced via depolymerisation now delivered at scale. Enables high-quality styrenics, including for food-grade and medical applications. Adds chemically recycled material t...
Heidelberg Materials takes Final Investment Decision for CCS project in UK – construction will start this year
The project in North Wales will make Heidelberg Materials’ Padeswood site the company’s second plant to deliver net-zero carbon captured evoZero® cement to customers across Europe